FGAM
TBPH icon

Financial Gravity Asset Management’s Theravance Biopharma TBPH Stock Holding History

Financial Gravity Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-9
Closed – – 1537
2019
Q2 		$0 Hold
9
– – ﹤0.01% 1645
2019
Q1 		$0 Buy
+9
New +$228 ﹤0.01% 1534

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Financial Gravity Asset Management's TBPH Position: Q3 2019 in Review

Financial Gravity Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2019, closing a stake of 9 shares.

Financial Gravity Asset Management first reported a position in TBPH in Q1 2019 and held it in 2 quarters. The position peaked at $0 in Q2 2019. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2019.

  • Financial Gravity Asset Management reported no remaining Theravance Biopharma position as of Q3 2019 after selling out during the quarter.
  • Financial Gravity Asset Management sold 9 Theravance Biopharma shares in Q3 2019.
  • Financial Gravity Asset Management first reported a position in Theravance Biopharma in Q1 2019 and held it in 2 quarters.
  • Financial Gravity Asset Management's Theravance Biopharma position peaked at $0 in Q2 2019.
  • 92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2019.

Based on Financial Gravity Asset Management's 13F filing for Q3 2019, filed 15 Oct 2019.